Department of Anaesthesia and Intensive Care, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
J Public Health (Oxf). 2024 May 29;46(2):256-266. doi: 10.1093/pubmed/fdae007.
efficacy of therapeutic cholecalciferol supplementation for severe COVID-19 is sparingly studied.
effect of single high-dose cholecalciferol supplementation on sequential organ failure assessment (SOFA) score in moderate-to-severe COVID-19.
participants with moderate to severe COVID-19 with PaO2/FiO2 ratio < 200 were randomized to 0.6 million IU cholecalciferol oral (intervention) or placebo.
primary outcome was change in Day 7 SOFA score and pre-specified secondary outcomes were SOFA and 28-day all-cause mortality.
in all, 90 patients (45 each group) were included for intention-to-treat analysis. 25(OH)D3 levels were 12 (10-16) and 13 (12-18) ng/ml (P = 0.06) at baseline; and 60 (55-65) ng/ml and 4 (1-7) ng/ml by Day 7 in vitamin D and placebo groups, respectively. The SOFA score on Day 7 was better in the vitamin D group [3 (95% CI, 2-5) versus 5 (95% CI, 3-7), P = 0.01, intergroup difference - 2 (95% CI, -4 to -0.01); r = 0.4]. A lower all-cause 28-day mortality [24% compared to 44% (P = 0.046)] was observed with vitamin D.
single high-dose oral cholecalciferol supplementation on ICU admission can improve SOFA score at Day 7 and reduce in-hospital mortality in vitamin D-deficient COVID-19. ClinicalTrials.gov id: NCT04952857 registered dated 7 July 2021. What is already known on this topic-vitamin D has immunomodulatory role. Observational and isolated intervention studies show some benefit in COVID-19. Targeted therapeutic vitamin D supplementation improve outcomes in severe COVID-19 is not studied in RCTs. What this study adds-high-dose vitamin D supplementation (0.6 Million IU) to increase 25(OH)D > 50 ng/ml is safe and reduces sequential organ failure assessment score, in-hospital mortality in moderate to severe COVID-19. How this study might affect research, practice or policy-vitamin D supplementation in vitamin D-deficient patients with severe COVID-19 is useful may be practiced.
治疗性胆钙化醇补充治疗严重 COVID-19 的疗效研究甚少。
研究单次大剂量胆钙化醇补充对中重度 COVID-19 序贯器官衰竭评估(SOFA)评分的影响。
将中重度 COVID-19 且 PaO2/FiO2 比<200 的患者随机分为 0.6 百万 IU 胆钙化醇口服(干预)或安慰剂组。
主要结局为第 7 天 SOFA 评分的变化,预设的次要结局为 SOFA 和 28 天全因死亡率。
共有 90 例患者(每组 45 例)纳入意向治疗分析。维生素 D 组和安慰剂组的 25(OH)D3 水平分别为 12(10-16)和 13(12-18)ng/ml(P=0.06),第 7 天分别为 60(55-65)和 4(1-7)ng/ml。维生素 D 组第 7 天的 SOFA 评分更好[3(95%CI,2-5)比 5(95%CI,3-7),P=0.01,组间差异-2(95%CI,-4 至-0.01);r=0.4]。维生素 D 组 28 天全因死亡率较低[24%比 44%(P=0.046)]。
在 ICU 入院时给予单次大剂量口服胆钙化醇补充可改善第 7 天的 SOFA 评分,并降低维生素 D 缺乏的 COVID-19 患者的住院死亡率。ClinicalTrials.gov 注册号:NCT04952857,登记日期:2021 年 7 月 7 日。关于这一主题,目前已知的内容是:维生素 D 具有免疫调节作用。观察性和孤立性干预研究表明 COVID-19 有一定益处。针对 COVID-19 的靶向治疗性维生素 D 补充改善结局的 RCT 研究尚未开展。本研究的新发现是:补充大剂量维生素 D(0.6 百万 IU)以增加 25(OH)D>50ng/ml 是安全的,可降低中重度 COVID-19 的序贯器官衰竭评估评分和住院死亡率。本研究对研究、实践或政策可能产生的影响是:维生素 D 缺乏的严重 COVID-19 患者补充维生素 D 可能是有用的。